Drug Interactions between ifosfamide and teprotumumab

Consumer information for this interaction is not currently available.

MONITOR: The concomitant use of teprotumumab with aminoglycosides, vancomycin, loop diuretics, or platinum-based chemotherapeutic agents may increase the risk of ototoxicity. The exact mechanism of this interaction is not fully established. Both teprotumumab and these agents have been individually associated with hearing impairment or damage to the inner ear structures. The risk may be greater in patients with pre-existing hearing loss, renal impairment, advanced age, or those receiving high doses or prolonged therapy. However, because topically administered aminoglycosides have minimal systemic absorption, the clinical relevance of this interaction for those agents is unclear.

MANAGEMENT: Caution is advised when teprotumumab is administered concomitantly with other drugs known to cause ototoxicity, such as aminoglycosides, vancomycin, loop diuretics, or platinum-based chemotherapeutic agents. The risks and benefits of treatment should be carefully evaluated before initiating concomitant therapy. Audiometric testing is recommended prior to starting treatment and periodically during therapy to monitor for early signs of hearing impairment. Patients should be advised to promptly notify their physician if they experience symptoms of ototoxicity, including hearing loss, tinnitus, vertigo, or a feeling of fullness in the ear.